8-K
Lunai Bioworks Inc. (LNAI)
View as plain text
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) oftheSecurities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2021
ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-54478 | 45-2559340 |
|---|---|---|
| (State<br>or other jurisdiction | (Commission<br>File Number) | (I.R.S.<br>Employer |
| of<br>incorporation) | Identification<br>No.) | |
| 2080 Century City East <br><br>Suite 906 <br><br>Los Angeles, CA 90067 <br><br>(Address of principal executive offices) | ||
| --- |
+1 (305) 918-1980
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications<br>pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material<br>pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications<br>pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications<br>pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | ENOB | The Nasdaq Stock Market LLC |
`
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On August 30, 2021, Enochian Biosciences Inc. (the “Company”) issued a press release announcing the appointment of Dr. Peter Piot, KCMG, FRCP and Dr. Richard Whitley, MD to the Company’s Scientific Advisory Board. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
|---|---|
| ExhibitNo. | Description |
| --- | --- |
| 99.1 | Press Release dated August 30, 2021. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENOCHIAN BIOSCIENCES, INC. | |
|---|---|
| By: | /s/ LuisaPuche |
| Name:<br>Luisa Puche<br> Title: Chief Financial Officer |
Date: August 30, 2021
Exhibit 99.1
Distinguished Scientific and Public HealthLeaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19and Influenza Variants
LOS ANGELES, August 30, 2021 (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a Scientific Advisory Board (SAB) focused on potential inhaled treatment and prevention of any current or future variants of SARS-CoV-2 – the virus that causes COVID-19 – and Influenza.
| ● | Dr. Peter Piot***,KCMG, FRCP, FMedSci, Chairperson*** of the SAB, is the Handa Professor of Global Health, London School of Hygiene and Tropical<br>Medicine, former founding Director of UNAIDS and co-discoverer of the Ebola virus. He is also a member of the US National Academy<br>of Medicine. |
|---|---|
| ● | Dr. Richard Whitley, MD,<br>Distinguished Professor, University of Alabama Birmingham, is a leading basic and clinical researcher who has published more than<br>380 scientific articles. |
“I have been working on pandemics for nearly 50 years, and was blown away by the genius of the inventor, Dr. Serhat Gumrukçu, and the sophistication and elegance of the scientific approach to potentially treat and prevent any variants of SARS-CoV-2 and Influenza,” said Dr. Piot. “If the impressive results in animal models are confirmed in people, there is the potential to contribute significantly to fighting COVID-19. Perhaps as important, it is possible that Enochian’s products could prevent future pandemic threats from corona- and influenza viruses.”
“I am excited to be involved with Enochian BioSciences as they try to move quickly to advance products that could potentially be important to control and, ultimately end, the COVID-19 pandemic,” Dr. Whitley said. “The Delta variant reproduces so quickly that even vaccinated people with no symptoms can have as much virus in their airways as unvaccinated people, contributing to rapid spread. Enochian’s unique and innovative approach to kill cells infected with the virus in the nose, mouth and lungs could potentially both limit illness but also spread for a win-win.”
Dr. Mark Dybul, Enochian’s CEO said, “We are thrilled that some of the top experts in the world seem as excited as we are about the potential for our products to play a key role in combating COVID-19, but also the potential for them to help prevent two of the greatest pandemic threats for the future – Influenza and another Coronavirus. The experience and knowledge the SAB brings will help accelerate Enochian’s efforts to advance the research and, we hope, ultimately to save lives.”
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit Enochianbio.com
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contact: ir@enochianbio.com
# # #